161.
Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus
by Shah, Manan, PharmD, PhD
Clinical therapeutics, 2013, Vol.35 (4), p.486-497
162.
GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis
by Li, C
European journal of clinical microbiology & infectious diseases, 2013, Vol.32 (7), p.859-868
163.
JNK3 Mediates Paraquat- and Rotenone-Induced Dopaminergic Neuron Death
by Choi, Won-Seok
Journal of neuropathology and experimental neurology, 2010, Vol.69 (5), p.511-520
164.
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
by DUBE, Michael P
AIDS (London), 2005, Vol.19 (16), p.1807-1818
165.
A parametric analysis of olanzapine-induced weight gain in female rats
by COOPER, G. D
Psychopharmacologia, 2005, Vol.181 (1), p.80-89
166.
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
by Bergman, Liesbeth
The Lancet (British edition), 2000, Vol.356 (9233), p.881-887
167.
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
by Brinkman, Kees
The Lancet (British edition), 1999, Vol.354 (9184), p.1112-1115
168.
Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study
by Schortgen, Frédérique
The Lancet (British edition), 2001, Vol.357 (9260), p.911-916
169.
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
by den Brinker, M
AIDS (London), 2000, Vol.14 (18), p.2895-2902
170.
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
by MARTINEZ, Esteban
AIDS (London), 2001, Vol.15 (10), p.1261-1268
171.
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
by Giovannoni, G
Journal of neurology, neurosurgery and psychiatry, 2000, Vol.68 (4), p.423-428
172.
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial
by Nisbet-Brown, Eric
The Lancet (British edition), 2003, Vol.361 (9369), p.1597-1602
173.
The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate Cancer
by Smith, J. C
The journal of clinical endocrinology and metabolism, 2001, Vol.86 (9), p.4261-4267
174.
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study
by Martínez, Esteban
The Lancet (British edition), 2001, Vol.357 (9256), p.592-598
175.
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
by Mittan, Daniella
The journal of clinical endocrinology and metabolism, 2002, Vol.87 (8), p.3656-3661
176.
Idiosyncratic drug reactions: the reactive metabolite syndromes
by Knowles, Sandra R
The Lancet (British edition), 2000, Vol.356 (9241), p.1587-1591
177.
Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment
by Crawford, Bronwyn A. L
The journal of clinical endocrinology and metabolism, 2003, Vol.88 (7), p.3167-3176
178.
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
by Hetherington, Seth
Clinical therapeutics, 2001, Vol.23 (10), p.1603-1614
179.
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
by SULKOWSKI, Mark S
AIDS (London), 2004, Vol.18 (17), p.2277-2284
180.
Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation
by Schmidt, M.
Alimentary pharmacology & therapeutics, 2012, Vol.35 (1), p.165-174
